Evolocumab - a new era in the treatment of dyslipidemia

Abstract

Effects of evolocumab are based on selective binding to PCSK9, which is specifically inhibited binding isoenzyme LDL-R.

Keywords

• Evolocumab
• PCSK9
• LDL-cholesterol
• therapy